STOCK TITAN
  1. Home
  2. News
  3. NRXP

NRX Pharmaceuticals, Inc. - NRXP STOCK NEWS

Welcome to our dedicated page for NRX Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals stock.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage, small-molecule pharmaceutical company dedicated to developing novel therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company's flagship products include ZYESAMI (Aviptadil), aimed at treating COVID-related respiratory failure, and NRX-100/101, the first sequential drug regimen specifically designed for bipolar depression in patients with acute suicidal ideation and behavior.

Recently, NRX Pharmaceuticals announced a public offering of its common stock to raise funds for working capital, general corporate purposes, and to repay certain debts. The proceeds will also support the initiation of a national treatment protocol and a safety database.

Among its most notable developments, the company is advancing NRX-101, designated as an FDA Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX Pharmaceuticals has strategic partnerships with Alvogen and Lotus for the development and marketing of NRX-101.

The company also oversees Hope Therapeutics, focusing on the development and marketing of IV ketamine for the acute treatment of suicidality and depression, leveraging a digital therapeutic-enabled platform to augment clinical benefits.

NRX Pharmaceuticals' robust pipeline includes plans for a New Drug Application for HTX-100 (IV ketamine) based on promising clinical trial results. It has also received Fast Track Designation from the FDA for the development of ketamine as part of its treatment protocol for acute suicidality.

Furthermore, NRX Pharmaceuticals is exploring the use of NRX-101 for chronic pain and complicated UTI, marking its potential to address significant unmet medical needs across various therapeutic areas. The company remains committed to improving patient outcomes and advancing its innovative therapies through rigorous clinical trials and strategic collaborations.

News

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders

Rhea-AI Summary
NRx Pharmaceuticals authorizes Dividend and Royalty Rights to NRXP Shareholders and warrant holders, distributing 49% of HOPE Therapeutics stock and 1% of Ketamine sales. Proxy voting for special meeting on March 21, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.19%
Tags
none
-
News

NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales

Rhea-AI Summary
NRx Pharmaceuticals, Inc. takes action to protect shareholder value by addressing short sellers through proposed changes in corporate name, CUSIP number, and potential reverse split. The Company aims to ensure compliance with Nasdaq listing rules and prevent naked short sales positions in its securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.38%
Tags
none
-
News

NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)

Rhea-AI Summary
NRx Pharmaceuticals and HOPE Therapeutics partner with Conversio Health and Nephron Pharmaceuticals to provide IV Ketamine to patients and clinics, aiming to offer high-quality solutions and ensure ongoing supply. The Company is set to receive its first allocation of ketamine by the end of March 2024, with plans to commence sales once technical aspects are finalized.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.14%
Tags
none
News

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

Rhea-AI Summary
NRx Pharmaceuticals announces completion of Phase 2b/3 study for NRX-101 in Suicidal Bipolar Depression, triggering potential $4 million milestone payment and further development by partners. Positive data could lead to up to $329 million in milestone payments and royalties. Top-line data expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.72%
Tags
clinical trial
-
News

NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share

Rhea-AI Summary
NRx Pharmaceuticals, Inc. received $1.0 million in cash from an existing investor through the sale of approximately 2.7 million shares at $0.38 per share, along with warrants at $0.40 per share. This investment will support the company in reaching milestones in its development pipeline, including data for Suicidal Depression, Suicidal Bipolar Depression, and Chronic Pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.01%
Tags
none
-
News

NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million

Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) announces the pricing of its public offering, generating $1.5 million in gross proceeds. The company plans to use the funds for working capital, debt obligations, and corporate purposes. The offering includes an option for additional shares, with EF Hutton LLC as the book-runner. The company also secured a separate $1 million commitment from an existing investor. The Chairman highlights the strategic use of funds to extend the company's runway, launch HOPE Therapeutics, and service debt obligations. The offering is expected to close on February 28, 2024, subject to customary conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.31%
Tags
offering
News

/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./

Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces the pricing of a $1.5 million underwritten public offering of common stock at $0.30 per share, with plans to use the net proceeds for working capital, general corporate purposes, and debt obligations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.31%
Tags
none
-
News

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) plans an underwritten public offering of common stock to raise capital for working capital, general corporate purposes, and debt repayment. The offering's completion is subject to market conditions, with EF Hutton LLC as the sole book-running manager.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.31%
Tags
offering
-
News

NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024

Rhea-AI Summary
NRx Pharmaceuticals announced key updates including awarding founding shares in HOPE Therapeutics to shareholders, a dividend proposal, and progress towards manufacturing ketamine supplies. Dr. Javitt will present at the BIO CEO & Investor Conference with a focus on expanding ketamine offerings and digital therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
none
News

NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024

Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) announces completion of initial manufacture of Ketamine for IV infusion, plans to file FDA New Drug Application for acute suicidality treatment, and initiates pre-IPO offering of shares for qualified investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
none

FAQ

What is the current stock price of NRX Pharmaceuticals (NRXP)?

The current stock price of NRX Pharmaceuticals (NRXP) is $1.23 as of November 21, 2024.

What is the market cap of NRX Pharmaceuticals (NRXP)?

The market cap of NRX Pharmaceuticals (NRXP) is approximately 14.6M.

What is NRX Pharmaceuticals' primary focus?

NRX Pharmaceuticals focuses on developing novel therapeutics for central nervous system disorders and life-threatening pulmonary diseases.

What are NRX Pharmaceuticals' key products?

The key products include ZYESAMI (Aviptadil) for COVID-related respiratory failure and NRX-100/101 for bipolar depression with acute suicidal ideation.

What is the significance of NRX-101?

NRX-101 is an FDA-designated Breakthrough Therapy aimed at treating suicidal treatment-resistant bipolar depression and chronic pain.

Who are NRX Pharmaceuticals' strategic partners?

NRX Pharmaceuticals has partnered with Alvogen and Lotus for the development and marketing of NRX-101.

What recent developments has NRX Pharmaceuticals announced?

The company has announced a public offering to raise funds for working capital, initiating a national treatment protocol, and repaying debts.

What is Hope Therapeutics?

Hope Therapeutics is a subsidiary of NRX Pharmaceuticals, focusing on the development and marketing of FDA-approved intravenous ketamine for acute suicidality and depression.

What is the purpose of the public offering announced by NRX Pharmaceuticals?

The public offering aims to raise funds for working capital, general corporate purposes, and to repay certain outstanding debts.

What are the future plans for NRX-101?

NRX Pharmaceuticals plans to expand NRX-101’s use for chronic pain and complicated UTI, and potentially submit a New Drug Application based on clinical trial results.

Has NRX Pharmaceuticals received any special designations from the FDA?

Yes, NRX Pharmaceuticals has received Fast Track Designation from the FDA for the development of ketamine (NRX-100) as part of its treatment protocol for acute suicidality.

What is the financial condition of NRX Pharmaceuticals as of the latest update?

As of the latest update, NRX Pharmaceuticals is in the process of raising funds through a public offering and has received $5 million from a milestone payment, improving its working capital situation.

Stock NRXP logo
NRX Pharmaceuticals, Inc.

Nasdaq:NRXP

NRXP Rankings

#5415 Ranked by Market Cap
N/A Ranked by Dividends

NRXP Stock Data

14.63M
9.24M
23.56%
6.05%
6.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMINGTON